# China Pharmaceutical University

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/china-pharmaceutical-university/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 56.5 |
| Citations | 3,638,220 |
| City | Nanjing |
| Country | CN |
| Description | China Pharmaceutical University is a research organisation in Nanjing, CN. OpenAlex records 39,318 works and 3,638,220 citations for it. 14,710 researchers list it as their most recent affiliation. |
| Homepage | https://www.cpu.edu.cn |
| OpenAlex ID | https://openalex.org/I161716053 |
| Researchers | 14,710 |
| ROR ID | https://ror.org/01sfm2718 |
| Type | education |
| Wikidata ID | https://www.wikidata.org/wiki/Q5099853 |
| Works | 39,318 |

## University papers

Showing 12 of 124.

- [EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update](https://scholariq.org/papers/eular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic/)
- [EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update](https://scholariq.org/papers/eular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic-2/)
- [EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update](https://scholariq.org/papers/eular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic-3/)
- [Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer](https://scholariq.org/papers/randomized-phase-iii-keynote-181-study-of-pembrolizumab-versus-chemotherapy-in/)
- [Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction](https://scholariq.org/papers/randomized-double-blind-placebo-controlled-phase-iii-trial-of-apatinib-in/)
- [COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas](https://scholariq.org/papers/covid-19-immune-features-revealed-by-a-large-scale-single-cell-transcriptome/)
- [Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)](https://scholariq.org/papers/guidelines-for-the-diagnosis-and-treatment-of-hepatocellular-carcinoma-2019/)
- [Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/regorafenib-plus-best-supportive-care-versus-placebo-plus-best-supportive-care/)
- [Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma](https://scholariq.org/papers/effect-of-camrelizumab-vs-placebo-added-to-chemotherapy-on-survival-and/)
- [Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study](https://scholariq.org/papers/brivanib-versus-sorafenib-as-first-line-therapy-in-patients-with-unresectable/)
- [The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer](https://scholariq.org/papers/the-keynote-811-trial-of-dual-pd-1-and-her2-blockade-in-her2-positive-gastric/)
- [Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring <i>c-Kit</i> Mutation or Amplification](https://scholariq.org/papers/phase-ii-open-label-single-arm-trial-of-imatinib-mesylate-in-patients-with/)

## University researchers

- [Na Lu](https://scholariq.org/researchers/na-lu/)
- [Renxiang Tan](https://scholariq.org/researchers/renxiang-tan/)
- [Jianjun Zhang](https://scholariq.org/researchers/jianjun-zhang-3/)
- [Siwen Li](https://scholariq.org/researchers/siwen-li/)
- [Weiwei Ding](https://scholariq.org/researchers/weiwei-ding/)
- [Qiao Lin](https://scholariq.org/researchers/qiao-lin/)
- [Qingran Yan](https://scholariq.org/researchers/qingran-yan/)
- [Yao Xu](https://scholariq.org/researchers/yao-xu/)

## University top topics

Showing 8 of 25.

- [Natural product bioactivities and synthesis](https://scholariq.org/topics/natural-product-bioactivities-and-synthesis/)
- [Traditional Chinese Medicine Analysis](https://scholariq.org/topics/traditional-chinese-medicine-analysis/)
- [Nanoplatforms for cancer theranostics](https://scholariq.org/topics/nanoplatforms-for-cancer-theranostics/)
- [Nanoparticle-Based Drug Delivery](https://scholariq.org/topics/nanoparticle-based-drug-delivery/)
- [Pharmacological Effects of Natural Compounds](https://scholariq.org/topics/pharmacological-effects-of-natural-compounds/)
- [Phytochemistry and Biological Activities](https://scholariq.org/topics/phytochemistry-and-biological-activities/)
- [Advanced biosensing and bioanalysis techniques](https://scholariq.org/topics/advanced-biosensing-and-bioanalysis-techniques/)
- [RNA Interference and Gene Delivery](https://scholariq.org/topics/rna-interference-and-gene-delivery/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.